Clinical trials · North Carolina
Down Syndrome clinical trials in North Carolina
We’re tracking 116 recruiting down syndrome studies with a site in North Carolina — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in North Carolina
- NCT06680752RecruitingPhase 1/Phase 2
A car-t cell therapy trial for AML or MDS
This trial tests a new CAR-T cell therapy, ARD103, for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or is not responding to treatment. It aims to see if this therapy can help control the disease.
Charlotte, North CarolinaAges 18 years+ - NCT05329935Recruiting
Registry for children with congenital thymus missing
This registry follows children born with congenital athymia (a missing or non-working thymus). It collects information around treatment with RETHYMIC, which may help researchers better understand how care and outcomes look over time.
Durham, North CarolinaAges birth–21 years - NCT06656494RecruitingPhase 1
New drug combo for myeloid blood cancers
This trial tests a new drug (ICP-248) combined with standard treatment azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). It aims to find out if the combo is safe and effective for those who haven't been helped by other treatments or cannot have strong chemotherapy.
Chapel Hill, North CarolinaAges 18 years+ - NCT06639984RecruitingPhase 2
Psyllium for kids with IBS
This study tests if psyllium, a fiber supplement, helps reduce belly pain and other symptoms in children with irritable bowel syndrome (IBS). It may be an option if standard treatments haven't worked well.
Durham, North CarolinaAges 12–17 - NCT03850574RecruitingPhase 1/Phase 2
Tuspetinib for relapsed or hard-to-treat AML
This early-phase study tests tuspetinib in people with AML that has come back or did not respond to treatment. The goal is to learn whether it is safe and tolerable, how the drug behaves in the body, and whether it shows signs of benefit.
Durham, North CarolinaAges 18 years+ - NCT06508164Recruiting
International registry for rare RYR2 variants
This study creates a registry for people with rare changes in the RYR2 gene that affect heart function. Researchers will collect information to better understand these conditions and improve care.
Durham, North CarolinaAges Any age - NCT06472765Enrolling by invitation
Study of the Vaginal Ecosystem in Healthy Women
This study looks at the natural balance of bacteria and other factors in the vagina of healthy women. It aims to learn more about what a healthy vaginal ecosystem looks like.
Winston-Salem, North CarolinaAges 18–89 - NCT06428019RecruitingPhase 3
Comparing drug combinations for untreated CLL or SLL
This trial tests two different drug combinations (venetoclax with obinutuzumab or with acalabrutinib) to see how they affect the risk of tumor lysis syndrome in people with untreated CLL or SLL. It may help find the safest and most effective way to start treatment.
Charlotte, North CarolinaAges 18 years+ - NCT06395285RecruitingPhase 1
Testing DF-003 for ROSAH syndrome with eye inflammation
This trial tests an oral medication called DF-003 for people with ROSAH syndrome who have eye inflammation (uveitis). The goal is to see if the drug is safe and tolerable. It might help reduce eye inflammation and other symptoms.
Durham, North CarolinaAges 18–65 - NCT06112418Recruiting
Personalized vs standard care to prevent heart attacks
This trial compares two ways to prevent heart attacks and strokes: one uses a special heart CT scan to guide care, the other uses standard risk factors like blood pressure and cholesterol. You may be eligible if you are older (men over 55, women over 65) and have diabetes, prediabetes, or metabolic syndrome.
Morehead City, North CarolinaAges 55 years+ - NCT01137643Recruiting
Sharing blood and tissue samples for blood cancer research
This trial collects tissue, blood, and other body fluid samples from people with blood-related cancers. The goal is to help researchers study these diseases by building a source of samples for future testing.
Chapel Hill, North CarolinaAges 18–120 - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Chapel Hill, North CarolinaAges Any age - NCT05979441Enrolling by invitationPhase 3
Long-term safety of efgartigimod injection for myositis
This study tests the long-term safety and effectiveness of a subcutaneous (under-the-skin) version of efgartigimod for adults with active idiopathic inflammatory myopathy. It is for people who have already completed an earlier study of this medicine.
Chapel Hill, North CarolinaAges 18 years+ - NCT05953090Recruiting
Vaginal irritation study with device use and long follow-up
This trial studies a treatment for long-lasting vaginal/vulvar irritation caused by conditions like vaginal atrophy or certain skin conditions of the vulva. You would try the study product/device and be followed over time to see how symptoms recover.
Fayetteville, North CarolinaAges 18 years+ - NCT05918861RecruitingPhase 3
Tested heart-risk drug for people with recent heart-attack genetics
This trial studies whether dalcetrapib can lower future heart and blood-vessel risk in people who recently had an ACS (acute coronary syndrome, often a heart attack or unstable chest pain) and have a specific genetic marker. It may help people like you by targeting a risk pathway related to that genetic background.
Pinehurst, North CarolinaAges 45 years+ - NCT05905926Enrolling by invitationPhase 3
Tenapanor safety study for teens with constipation-predominant IBS
This trial checks the safety of tenapanor in children and teens (ages 6 to under 18) with IBS-C. It is only for people who finished a previous related study and agreed to continue follow-up.
Wilmington, North CarolinaAges 6–18 - NCT05905328RecruitingPhase 1/Phase 2
New drug to prevent and treat side effects of CAR T-cell therapy
This study tests an experimental drug, CTO1681, that may help prevent or treat cytokine release syndrome (CRS) — a common side effect of CAR T-cell therapy. It could make the recovery period safer and more comfortable.
Durham, North CarolinaAges 18 years+ - NCT05849662RecruitingPhase 1/Phase 2
Trametinib plus azacitidine for newly diagnosed JMML
This trial studies whether trametinib and azacitidine can control juvenile myelomonocytic leukemia (JMML) soon after diagnosis. It’s designed to test safety and how well the treatment works in children and young adults who meet specific leukemia and genetic criteria.
Charlotte, North CarolinaAges 1 month–21 years - NCT05737121RecruitingPhase 2
Study drug for bladder pain compared with lidocaine, heparin, or placebo
This Phase 2 trial tests VNX001 to see if it helps people with interstitial cystitis/bladder pain syndrome (IC/BPS) compared with its separate ingredients (lidocaine and heparin) or a placebo (inactive treatment). You may be eligible if you have had IC/BPS for months and recently had a moderate-to-severe bladder pain flare.
Winston-Salem, North CarolinaAges 18 years+ - NCT05701917Recruiting
Clot-busting device versus blood thinners for leg clot
This study compares a clot-removal device (ClotTriever) plus standard care versus standard blood thinners alone for a deep vein clot in the leg. It aims to see which approach better improves leg symptoms and outcomes.
Asheville, North CarolinaAges 18 years+ - NCT05671757RecruitingPhase 1/Phase 2
Daratumumab for primary antiphospholipid syndrome
This early-phase study tests daratumumab, an immune-targeting drug, for people with primary antiphospholipid syndrome (APS). It aims to see whether it can reduce APS activity and improve outcomes while you continue your usual blood-thinning treatment.
Durham, North CarolinaAges 18–65 - NCT05564390RecruitingPhase 2
MyeloMATCH screening to match you to AML or MDS treatment
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
Chapel Hill, North CarolinaAges 18 years+ - NCT05462106RecruitingPhase 1/Phase 2
ACI-24.060 study for early Alzheimer’s in adults and Down syndrome
This Phase 1/2 study tests an Alzheimer’s treatment called ACI-24.060 to see if it affects the disease in people with early Alzheimer’s changes. It includes two groups: older adults with early symptoms and people with Down syndrome who also show Alzheimer’s-related changes on brain scans.
Matthews, North CarolinaAges 35–85 - NCT05267821RecruitingPhase 2/Phase 3
Testing anakinra to reduce inflammation in pediatric sepsis MODS
This study tests whether a medicine called anakinra can “turn down” harmful inflammation in children with severe illness from sepsis. It aims to improve organ function when multiple organs are starting to fail.
Durham, North CarolinaAges 1 day–17 years
Down Syndrome trials by city in North Carolina
Where these studies are running in North Carolina
Institutions with a site for the recruiting down syndrome studies listed above.
- Duke University Medical Center · 8 studies
- Duke University School of Medicine · 2 studies
- UNC Lineberger Comprehensive Cancer Center · 2 studies
- University of North Carolina at Chapel Hill · 2 studies
- Wake Forest University Health Sciences · 2 studies
- Atrium Health
- Atrium Health /ID# 267219
- Atrium Health Wake Forest Baptist Medical Center /ID# 273142
What taking part in a down syndrome study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Down Syndrome trials in other states
Common questions
- Are there down syndrome clinical trials in North Carolina?
- Yes. We're currently tracking 116 recruiting down syndrome studies with a site in North Carolina, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a down syndrome study in North Carolina?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in North Carolina to take part?
- Not necessarily. These studies have a site in North Carolina, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a down syndrome trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New down syndrome studies open in North Carolina regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.